Skip to main content
Premium Trial:

Request an Annual Quote

AnPac Bio Regains Compliance With Nasdaq Minimum Bid Price Requirement

NEW YORK — Chinese cancer diagnostics firm AnPac Bio-Medical Science said on Wednesday that it has regained compliance with the Nasdaq's minimum $1 per share bid requirement.

Earlier this year, AnPac Bio said that it had received notice from the Nasdaq that the exchange planned to delist the company's stock due to its failure to meet the minimum bid requirement. Around that time, the firm inked an investment agreement to raise roughly $3.7 million.

AnPac Bio said that it will continue to be monitored for compliance by the Nasdaq until mid-2023 pursuant to a Nasdaq decision in June that the company had regained compliance with other listing requirements. If AnPac Bio is found to be out of compliance during this period, its shares will again face delisting.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.